Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics, Inc. Schedule 13G: Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report beneficial ownership of 3,055,027 shares of Avalo Common Stock, representing 5.81% of the class as reported.
The filing states the ownership figures are calculated using 52,565,572 shares outstanding as of May 8, 2026, per the issuer's 10-Q. The statement is a joint filing by the named reporting persons and identifies Deep Track Capital, LP as the relevant entity for which Kroin may be considered a control person.
Point72 Asset Management and affiliates reported beneficial ownership of 2,710,817 shares of Avalo Therapeutics common stock, representing 5.2% of the class as of the close of business on May 22, 2026. The filing states Point72 Asset Management and Point72 Capital Advisors have shared voting and dispositive power over these shares through holdings of Point72 Associates, and that Steven A. Cohen controls the reporting entities. The statement is filed as a joint Schedule 13G under Rule 13d-1(k) and is accompanied by a Joint Filing Agreement (Exhibit 99.1).
Avalo Therapeutics, Inc. Chief Strategy Officer Jennifer Riley reported an acquisition of 34,200 shares of Common Stock on May 21, 2026, at a stated price of $0.00 per share. After this award, she directly holds 36,855 shares.
According to the footnote, this represents performance stock units granted on August 19, 2025. Each unit is a contingent right to one share, tied to performance goals that the Compensation Committee certified on May 21, 2026. The shares are scheduled to fully vest on August 19, 2028, assuming her continued service.
Avalo Therapeutics, Inc. disclosed that its Chief Financial Officer, Christopher Ryan Sullivan, acquired 39,900 shares of Common Stock on May 21, 2026 in a grant/award transaction with a stated price of $0.0000 per share. Following this award, he directly holds 40,323 shares of Common Stock.
According to the accompanying disclosure, these shares relate to performance stock units (PSUs) originally granted on August 19, 2025, each representing a contingent right to receive one share of Common Stock upon achievement of specified performance goals. The Compensation Committee certified achievement of those goals on May 21, 2026, and the shares subject to the PSUs are scheduled to fully vest on August 19, 2028, subject to Sullivan’s continued service through that vesting date.
Avalo Therapeutics, Inc. reported that Chief Legal Officer Paul Varki acquired 24,300 shares of Common Stock through a compensation award. These shares relate to performance stock units granted earlier, each representing a right to one share upon meeting performance goals.
The Compensation Committee certified achievement of the required goals on May 21, 2026. As a result, the shares will fully vest on August 19, 2028, if Varki continues in service through that date. Following this award, he holds 27,934 shares directly.
Avalo Therapeutics, Inc. reported that its Chief Medical Officer, Mittie Doyle, acquired 43,500 shares of Common Stock through a compensation-related award. The transaction was coded as a grant or award, with a price per share of $0.0000, indicating no cash purchase.
Following this award, Doyle directly holds 47,122 shares of Avalo Therapeutics common stock. The award relates to performance stock units granted on August 19, 2025, which will fully vest on August 19, 2028 if specified performance goals remain achieved and Doyle continues in service through that vesting date.
Avalo Therapeutics’ CEO Neil Garry Arthur received a large equity award tied to performance. He was granted 100,200 shares of Common Stock as a grant/award acquisition at a price of $0.00 per share, increasing his direct holdings to 190,314 shares.
According to the footnote, this represents performance stock units granted on August 19, 2025. Each unit converts into one share only if specific performance goals are met. The Compensation Committee certified achievement of those goals on May 21, 2026, and the shares are scheduled to fully vest on August 19, 2028, if he remains in service.
Avalo Therapeutics Chief Medical Officer Mittie Doyle reported an exercise-and-sell transaction in Avalo Therapeutics, Inc. common stock. On May 15, 2026, she exercised stock options to acquire 3,000 shares of common stock at $12.65 per share, then sold 3,000 shares in an open-market transaction at $18.76 per share.
After these transactions, she directly holds 3,622 shares of common stock and 128,625 stock options. The filing states the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Avalo Therapeutics, Inc. ownership disclosure: Logos Global Management and related reporting persons report beneficial ownership of 1,675,000 shares of Common Stock, equal to 3.2% of the class. The calculation uses 52,565,517 shares outstanding as of May 8, 2026.
The filing states the position comprises 675,000 shares of Common Stock and options to acquire 1,000,000 shares. Reporting persons disclaim group membership and sole beneficial ownership; shared voting and dispositive power are reported for the listed entities and individual.
Avalo Therapeutics, Inc. ownership disclosure: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report shared beneficial ownership totaling 2,455,655 shares as of March 31, 2026 and state a 9.99% ownership position under a conversion cap.
The Fund directly holds 662,968 shares and Series C preferred stock convertible into up to 2,483,099 shares, subject to a Beneficial Ownership Blocker that prevents conversion above the 9.99% threshold. Share counts reference 22,788,452 shares outstanding as of March 18, 2026.